FilipaLynceMD

Oncology • Boston, MA

Breast Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Lynce is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lynce's full profile

Already have an account?

Office
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3000

Education & Training

MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 2008 - 2011

Certifications & Licensure

MA State Medical License 2020 - 2025
DC State Medical License 2008 - 2020
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease Start of enrollment: 2018 May 21
Active, not recruiting
Phase 2
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Start of enrollment: 2019 Apr 17
Active, not recruiting
Phase 1, Phase 2

Publications & Presentations

PubMed

30 citations
SAFE‐HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2‐Positive Breast Cancer and Reduced Left V...
Filipa Lynce, Ana Barac, Ming Tan, Federico M. Asch, Karen L. Smith
The Oncologist. 2017-05-01
7 citations
Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy: End of One Size Fits All∗
Ana Barac, Anne H. Blaes, Filipa Lynce
Journal of the American College of Cardiology. 2019-06-11
19 citations
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compr...
Katia E. Khoury, Filipa Lynce, Ana Barac, Xue Geng, Chau T. Dang
Breast Cancer Research and Treatment. 2021-01-05

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology

Lectures

SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Press Mentions

Inflammatory Breast Cancer Grant Allows Two Researchers to Test a New Tool for Diagnosing the Aggressive SubtypeMay 31st, 2022
Dr. Lynce on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBCFebruary 11th, 2020
Data Presented on PI3K Pathway Alterations at SABCS 2019December 10th, 2019
Join now to see all